Can-Fite BioPharma Ltd. (CANF)

1.24
AMEX : Health Technology
Prev Close 1.28
Day Low/High 1.24 / 1.28
52 Wk Low/High 1.18 / 2.75
Avg Volume 195.50K
Exchange AMEX
Shares Outstanding 19.98M
Market Cap 26.65M
EPS -0.30
P/E Ratio 8.53
Div & Yield N.A. (N.A)

Latest News

Can-Fite Reports First Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite Reports First Quarter 2018 Financial Results And Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today reported financial results for the three months...

Can-Fite's Piclidenoson Mechanism Of Action In Psoriasis Published In 'Journal Of Immunology Research'

Can-Fite's Piclidenoson Mechanism Of Action In Psoriasis Published In 'Journal Of Immunology Research'

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, today announced the publication of a paper entitled "Inhibition of...

Can-Fite To Present At The MicroCap Conference

Can-Fite To Present At The MicroCap Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Reports 2017 Financial Results & Provides Clinical Update

Can-Fite Reports 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced...

Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite To Present At The NASH 2nd Annual H.C. Wainwright Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, today announced...

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Announces $5 Million Registered Direct Offering

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI) , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has...

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite To Participate In Panel Discussions On Latest Drug Developments In NASH At The 30th Annual ROTH Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite To Present At The Inaugural LD Micro Virtual Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can Fite Reports On The Progress Of Its Phase II NASH Study With Drug Candidate Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an...

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can Fite Announces The Submission Of Safety Reports For Piclidenoson And Namodenoson To FDA And Other Regulatory Authorities Showing Favorable Safety Profile

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that it...

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Announces New Pre-Clinical Data Supporting A Novel Anti-NASH Mechanism Of Action For Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address liver and inflammatory diseases, announced today that...

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite To Present At BIO CEO & Investor Conference

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small-molecule drugs that address cancer, liver disease and inflammatory diseases, announced today...

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite Receives From Gebro Holdings $2,200,000 Payment As Part Of Distribution Agreement For Piclidenoson In 3 European Countries

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite 12 Months' Activities & Milestones For 2018

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced its...

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite Signs Multi-Million Dollar Distribution Agreement For Piclidenoson In 3 European Countries With Gebro Holdings

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Data Demonstrate A Significant Anti-NASH Effect And Represent The Basis For Can-Fite's Collaborative Research Program With Dr. Safadi. (Graphic: Business Wire)

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite Reports On The Progress Of Its Phase II Liver Cancer With Namodenoson

Can-Fite BioPharma Ltd. (NYSEAM:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its...

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite Reports Third Quarter 2017 Financial Results & Provides Clinical Update

Can-Fite BioPharma Ltd. (NYSE MKT:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today reported financial...

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite Enrolls First Patient In Phase II NAFLD/NASH Study With Namodenoson

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that...

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite's Former Subsidiary OphthaliX Successfully Completes Merger With Wize Pharma

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite Announces Enrollment Of First Patient In Its ACRobat Phase III Trial Of Piclidenoson In Rheumatoid Arthritis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite Issued Patent In Korea For Piclidenoson In The Treatment Of Psoriasis

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the...

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite To Present At 2017 AASLD Liver Meeting Conference In Washington, D.C.

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it will...

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite CEO Dr. Pnina Fishman To Present As Expert Speaker At NASH Summit Europe In Frankfurt, Germany On October 12, 2017

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced that...

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite Files Patent Application To Treat Cytokine Release Syndrome, A Potentially Life-Threatening Complication Of CAR-T Cell Therapy

Can-Fite BioPharma Ltd. (NYSE American:CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite Receives Milestone Payment From CKD Pharmaceuticals Its Distribution Partner In Korea

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced it has...

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite Successfully Completes Human Cardiodynamic Safety Trial For Piclidenoson

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today announced it has successfully...

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite's Phase II NAFLD/NASH Trial With Namodenoson Set To Commence Patient Enrollment Following Conclusion Of Successful Clinical Investigator Meeting

Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, announced today that it...

TheStreet Quant Rating: E+ (Sell)